Vyome Holdings, Inc. (HIND)
NASDAQ:HIND
Want to see HIND full AI Analyst Report?
HIND Stock Chart & Stats
$5.42
--
Market closed
$5.42
--
Day’s Range― - ―
52-Week Range$1.75 - $18.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)35.04K
Market Cap
$15.23M
Enterprise Value$3.50M
Total Cash (Recent Filing)$8.80M
Total Debt (Recent Filing)$22.55K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.80
Shares Outstanding7,018,528
10 Day Avg. Volume28,056
30 Day Avg. Volume35,037
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue2.60
Enterprise Value/Gross Profit5.41
Enterprise Value/Ebitda-0.26
Forecast
1Y Price Target
$11.50Price Target Upside112.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Recent Positive EquityVery low TTM debt-to-equity (~0.003) and positive equity in TTM and 2025 provide balance-sheet flexibility. That reduces near-term solvency pressure, supports access to financing or strategic M&A, and gives management optionality while executing a multi-month repositioning plan.
Healthy Gross MarginA gross margin near 48.6% indicates underlying unit economics are solid; if management stabilizes revenue and controls operating costs, the company has structural ability to convert additional sales into operating leverage and move toward profitability over a multi-month horizon.
Capital-structure Tightening ApprovedShareholder approval to cut authorized shares materially (300M to 50M) tightens capital structure and lowers dilution risk going forward. This governance action, plus board continuity, supports shareholder-aligned execution of strategic repositioning and preserves equity value over the medium term.
Bears Say
Sharp TTM Revenue DeclineA 44.6% TTM revenue decline erodes scale and operating leverage, making fixed R&D and SG&A spend harder to sustain. Without a durable revenue recovery or new revenue streams, the top-line contraction materially increases execution risk for any multi-month strategic turnaround.
Persistently Negative Cash Flow And BurnAbout -$7.3M OCF/FCF TTM and multi-year negative cash flows show the business currently cannot self-fund. Continuous burn constrains strategic flexibility, heightens dilution risk from external funding needs, and pressures timelines for reaching sustainable operations.
Multi-year Losses And Weak Shareholder ReturnsConsistent negative ROE across multiple years and a past period of negative equity (2024) signal an inability to compound shareholder capital. This structural profitability weakness raises long-term execution risk for new strategic initiatives and limits internal capital generation.
Vyome Holdings News
HIND FAQ
What was Vyome Holdings, Inc.’s price range in the past 12 months?
Vyome Holdings, Inc. lowest stock price was $1.75 and its highest was $18.60 in the past 12 months.
What is Vyome Holdings, Inc.’s market cap?
Vyome Holdings, Inc.’s market cap is $15.23M.
When is Vyome Holdings, Inc.’s upcoming earnings report date?
Vyome Holdings, Inc.’s upcoming earnings report date is Nov 24, 2026 which is in 159 days.
How were Vyome Holdings, Inc.’s earnings last quarter?
Vyome Holdings, Inc. released its earnings results on May 28, 2026. The company reported -$0.15 earnings per share for the quarter, the consensus estimate of -$0.15 by $0.
Is Vyome Holdings, Inc. overvalued?
According to Wall Street analysts Vyome Holdings, Inc.’s price is currently Undervalued.
Does Vyome Holdings, Inc. pay dividends?
Vyome Holdings, Inc. does not currently pay dividends.
What is Vyome Holdings, Inc.’s EPS estimate?
Vyome Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vyome Holdings, Inc. have?
Vyome Holdings, Inc. has 7,018,528 shares outstanding.
What happened to Vyome Holdings, Inc.’s price movement after its last earnings report?
Vyome Holdings, Inc. reported an EPS of -$0.15 in its last earnings report, expectations of -$0.15. Following the earnings report the stock price went up 4.911%.
Which hedge fund is a major shareholder of Vyome Holdings, Inc.?
Currently, no hedge funds are holding shares in HIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings, Inc.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
HIND Stock 12 Month Forecast
Average Price Target
$11.50
▲(112.18% Upside)
Technical Analysis
Ownership Overview
6.49% Insiders
0.36% Mutual Funds
― Other Institutional Investors
93.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---